Canada is one of the first big markets where semaglutide goes off patent. IQVIA plans ongoing updates on pricing, coverage and generic uptake.
Recap by typeshit. Full story at IQVIA.
The estimate, shared by M Mohan, starts from about $141 billion in 2025, with North America holding roughly 62% and semaglutide and tirzepatide leading.
The Medicare GLP-1 Bridge pilot runs July 2026 through 2027, covering FDA-approved pills and shots with no deductible for eligible Part D enrollees.
The two drugs brought in $14.9 billion of Lilly's $23.0 billion fiscal Q2 revenue while US prices fell 9%, Trefis says. The Q3 report is expected around October 29.
Novo Nordisk is lowering what Wegovy costs in China, a fresh move in the race for the country's obesity drug market. No figures were given.
Healio
At the Cardiometabolic Health Congress, the UAB professor asked whether maximal weight loss is optimal and flagged that most non-diabetic patients quit GLP-1s within two years.
A sponsored-style explainer that walks through semaglutide versus tirzepatide and the post-shortage compounding limits, while featuring telehealth company Mochi Health.
Loading…